InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | 2026-02-11 | RA CAPITAL MANAGEMENT, L.P. | Director | Purchase | 3.69M | $16.00 | $59.04M | 5.97M | View ↗ | |
| 2026-02-09 | 2026-02-11 | Behbahani Ali | Director | Purchase | 937.5K | $16.00 | $15.00M | 6.04M | View ↗ | |
| 2026-02-09 | 2026-02-11 | Pardo Geoffrey B | Director | Purchase | 312.5K | $16.00 | $5.00M | 2.19M | View ↗ | |
| 2026-02-09 | 2026-02-11 | Khan Bilal Arshad | Director | Purchase | 135.0K | $16.00 | $2.16M | 251.4K | View ↗ | |
| 2026-02-09 | 2026-02-10 | Nielsen Kirk G. | Director | Purchase | 165.0K | $16.00 | $2.64M | 3.31M | View ↗ |
No annual data found.
SpyGlass Pharma, Inc. GAAP EPS of -$5.72
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit